Source Feed: The Globe and Mail
Author: Ann Hui
Publication Date: September 30, 2025 - 20:56
Mohawk Institute Residential School reopens as a museum
September 30, 2025
Among the very first group of visitors to walk through the doors of the old Mohawk Institute − the former residential school that officially reopened as a museum this week − was 68-year-old Beverly Albrecht. Unlike most of the visitors, Ms. Albrecht didn’t require the assistance of signs or a guide to find her way around.
That’s because every inch and step of this building was imprinted on her from the time she was a child. From 1966 until 1970 – from the time she was seven until about 11 – Ms. Albrecht, a member of the Cayuga Nation, was a residential school student here. And it’s where, in the 1940s, Ms. Albrecht’s mother, too, was a residential school student.
Unpublished Newswire
Doctors are calling on provinces to bolster addiction treatment services in response to growing opioid use among young people, a crisis they fear will escalate for decades to come if immediate action is not taken.In a Canadian Medical Association Journal (CMAJ) editorial published Monday, physicians Shannon Charlebois and Shawn Kelly say the escalation of opioid use among youth is being overlooked. Existing addiction services, they say, are also inadequate to meet the needs of young people with opioid use disorder, or OUD.
October 27, 2025 - 00:01 | Alanna Smith | The Globe and Mail
The Alberta government is expected to introduce back-to-work legislation on Monday to force striking teachers to return to classrooms after three weeks, raising fears among labour advocates that the province will invoke the Charter’s notwithstanding clause to override workers’ rights. More than 750,000 students have been out of class since Oct. 6, after negotiations between the Alberta Teachers’ Association and the province broke down.
October 26, 2025 - 21:24 | Meera Raman | The Globe and Mail
Health Canada has for the first time approved a disease-modifying drug for Alzheimer’s disease, a watershed moment that offers hope for patients but does not guarantee that the complex and expensive intravenous therapy will be widely available in this country. The federal regulator on Friday granted a conditional authorization for lecanemab, an antibody drug that can slow the progression of the disease for some people with mild cognitive impairment or early-stage dementia owing to Alzheimer’s.
October 26, 2025 - 21:08 | Kelly Grant | The Globe and Mail
Comments
Be the first to comment